Richard Scolyer, page-5

  1. 3,592 Posts.
    lightbulb Created with Sketch. 788

    Your reference to God and his ' in your own mind ' flaws Raki make no sence when one references God in that manner without considering eternal life..

    Everyone wants to go to heaven but no one wants to die..

    Anyway i believe Richards journey highlights a serious conversation need be had as to why FDA and TGA and alike insist on taking choice away from people who are dieing as to not be able to choose there own treatments when it comes to trialing new treatments..

    Why do they have to have had chemotherapy with all its negative aspects to start on Imugenes or alike trials when clearly they know what chemo does to the patients immune system vs how important ones immune system is with a treatment such as Imugenes..it could be argued chemo is counter-productive to Imugenes treatments

    Chemo has been paid for..its made BP billions already..maybe it's time for less focus on the money and more on the people..let's face it chemotherapy burns the person from the inside to outside with all its negative effects on the person..there will be a day when people say remember when they used that poison chemotherapy to treat cancer..yer can't believe they did that..

    Let the person decide for themselves..their body their choice seems to be the theme these days bar cancer treatment..

    dyor just my opinion and never advice




 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.4¢
Change
0.001(7.69%)
Mkt cap ! $104.5M
Open High Low Value Volume
1.2¢ 1.4¢ 1.2¢ $267.3K 20.57M

Buyers (Bids)

No. Vol. Price($)
5 788815 1.3¢
 

Sellers (Offers)

Price($) Vol. No.
1.4¢ 13241534 29
View Market Depth
Last trade - 16.10pm 20/06/2025 (20 minute delay) ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.